Eli Lilly and Company
$ 903.99
-0.11%
16 Apr - close price
- Market Cap 809,087,992,000 USD
- Current Price $ 903.99
- High / Low $ 920.00 / 898.15
- Stock P/E 39.32
- Book Value 29.66
- EPS 22.99
- Next Earning Report 2026-04-30
- Dividend Per Share $6.00
- Dividend Yield 0.66 %
- Next Dividend Date -
- ROA 0.19 %
- ROE 1.01 %
- 52 Week High 1132.06
- 52 Week Low 620.46
About
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Analyst Target Price
$1209.86
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-04 | 2025-10-30 | 2025-08-07 | 2025-05-01 | 2025-02-06 | 2024-10-30 | 2024-08-08 | 2024-04-30 | 2024-02-06 | 2023-11-02 | 2023-08-08 | 2023-04-27 |
| Reported EPS | 7.54 | 7.02 | 6.31 | 3.34 | 5.32 | 1.18 | 3.92 | 2.58 | 2.49 | 0.1 | 2.11 | 1.62 |
| Estimated EPS | 7.17 | 6.37 | 5.59 | 3.54 | 5.0668 | 1.47 | 2.6 | 2.46 | 2.22 | -0.13 | 1.98 | 1.73 |
| Surprise | 0.37 | 0.65 | 0.72 | -0.2 | 0.2532 | -0.29 | 1.32 | 0.12 | 0.27 | 0.23 | 0.13 | -0.11 |
| Surprise Percentage | 5.1604% | 10.2041% | 12.8801% | -5.6497% | 4.9972% | -19.7279% | 50.7692% | 4.878% | 12.1622% | 176.9231% | 6.5657% | -6.3584% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-04-30 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | 7.55 |
| Currency | USD |
Previous Dividend Records
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Payment Date | 2026-03-10 | 2025-12-10 | 2025-09-10 | 2025-06-10 | 2025-03-10 | 2024-12-10 | 2024-09-10 | 2024-06-10 | 2024-03-08 | 2023-12-08 |
| Amount | $1.73 | $1.5 | $1.5 | $1.5 | $1.5 | $1.3 | $1.3 | $1.3 | $1.3 | $1.13 |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: LLY
2026-04-17 13:44:59
Morgan Stanley has increased its price target for Eli Lilly and Company (LLY) to $1,327 from $1,313, maintaining an Overweight rating due to updated biopharma model assumptions and recent industry data. Additionally, Eli Lilly reported positive Phase 3 trial results for its drug Jaypirca in combination therapy for relapsed or refractory CLL/SLL, showing significant improvement in progression-free survival. The company continues to be recognized for its innovative drug development in various therapeutic areas.
2026-04-17 12:10:10
Definium Therapeutics is developing DT120, an LSD-based candidate, for generalized anxiety disorder and major depression. The company expects late-stage data for its anxiety trials in the coming months, aiming for potential approval by next year, following positive Phase 2 results. If successful, DT120 could offer a new treatment option for anxiety, leveraging an administration model similar to Johnson & Johnson's Spravato, and also has potential in the depression market.
2026-04-17 11:09:23
Alterity Therapeutics has appointed Ann Cunningham, a biotech executive with over 25 years of commercial experience from companies like Lilly and Teva, as an independent Non-Executive Director. This strategic move strengthens Alterity's board with significant commercial and strategic expertise as the company prepares to advance its lead asset, ATH434, into Phase 3 development for Multiple System Atrophy (MSA). Cunningham's background includes instrumental roles in successful product launches and developing commercial strategies for innovative neurodegenerative and psychiatry therapies.
2026-04-16 22:52:49
Amazon Web Services (AWS) has launched Amazon Bio Discovery, an AI-powered drug discovery tool designed to accelerate the early-stage development of antibody therapies. This new agentic AI application provides scientists with access to specialized biological foundation models and allows them to use natural language to design and test novel drugs, aiming to overcome the challenges of integrating complex AI models into research. The platform has already demonstrated significant time savings in antibody design for Memorial Sloan Kettering Cancer Center, reducing a year-long process to just weeks.
2026-04-16 20:39:02
The Federal Circuit reversed a district court's invalidation of Teva's headache treatment patents, distinguishing its decision from the Amgen case. The patents claim methods of using humanized anti-CGRP antagonist antibodies to treat headaches, not the antibodies themselves. The CAFC found that the district court's grant of judgment as a matter of law was improper regarding both written description and enablement requirements.
2026-04-16 20:07:56
Pharmaceutical giant Eli Lilly has acquired Houston biotechnology startup CrossBridge Bio in a deal valued at approximately $300 million, including an upfront payment and a contingent milestone payment. This acquisition is expected to accelerate CrossBridge Bio's development of cancer-fighting drugs, currently in the preclinical phase, and strengthen Eli Lilly's oncology drug pipeline. This move further solidifies Eli Lilly's significant investment in Houston as a biotechnology hub, following plans for a $6.5 billion biomanufacturing plant in the area.
